Novartis/Orion Stalevo for Parkinson’s
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis/Orion's idiopathic Parkinson's disease therapy Stalevo (carbidopa, levodopa and entacapone) clears FDA June 11. The combination product adds entacapone (Novartis/Orion's Comtan) to the standard Parkinson's regimen of levodopa/carbidopa. Labeling says Stalevo can be used as a substitute for taking levodopa/carbidopa and Comtan separately. The firms have highlighted more convenient dosing as an advantage of the combo product (1Pharmaceutical Approvals Monthly Sept. 1, 2002, p. 59
You may also be interested in...
Novartis/Orion triple-combo Parkinson’s submission
Novartis and Orion Pharma submit NDA for first triple-combination Parkinson's disease therapy, the firms announce Aug. 26. The combination adds entacapone (Orion's Comtan) to the standard regimen for Parkinson's: levodopa and carbidopa. Entacapone, which is approved for patients with idiopathic Parkinson's disease who experience signs and symptoms of end-of-dose "wearing off," reduces the breakdown of levodopa, allowing it to remain therapeutically available for longer periods between doses. A triple-combination product would provide more convenient dosing, the firms sa
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.